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Abstract 
Background: The prevalence of human infections with the zoonotic pathogen Campylobacter jejuni is rising world‑
wide. Therefore, the identification of compounds with potent anti‑pathogenic and anti‑inflammatory properties for 
future therapeutic and/or preventive application to combat campylobacteriosis is of importance for global health. 
Results of recent studies suggested carvacrol (4‑isopropyl‑2‑methylphenol) as potential candidate molecule for the 
treatment of campylobacteriosis in humans and for the prevention of Campylobacter colonization in farm animals.
Results: To address this in a clinical murine infection model of acute campylobacteriosis, secondary abiotic IL‑10−/− 
mice were subjected to synthetic carvacrol via the drinking water starting 4 days before peroral C. jejuni challenge. 
Whereas at day 6 post‑infection placebo treated mice suffered from acute enterocolitis, mice from the carvacrol 
cohort not only harbored two log orders of magnitude lower pathogen loads in their intestines, but also displayed 
significantly reduced disease symptoms. Alleviated campylobacteriosis following carvacrol application was accom‑
panied by less distinct intestinal apoptosis and pro‑inflammatory immune responses as well as by higher numbers of 
proliferating colonic epithelial cells. Remarkably, the inflammation‑ameliorating effects of carvacrol treatment were 
not restricted to the intestinal tract, but could also be observed in extra‑intestinal organs such as liver, kidneys and 
lungs and, strikingly, systemically as indicated by lower IFN‑γ, TNF, MCP‑1 and IL‑6 serum concentrations in carvacrol 
versus placebo treated mice. Furthermore, carvacrol treatment was associated with less frequent translocation of 
viable C. jejuni originating from the intestines to extra‑intestinal compartments.
Conclusion: The lowered C. jejuni loads and alleviated symptoms observed in the here applied clinical murine model 
for human campylobacteriosis highlight the application of carvacrol as a promising novel option for both, the treat‑
ment of campylobacteriosis and hence, for prevention of post‑infectious sequelae in humans, and for the reduction of 
C. jejuni colonization in the intestines of vertebrate lifestock animals.
Keywords: Carvacrol, Anti‑pathogenic and anti‑inflammatory properties, Campylobacter jejuni, Secondary abiotic 
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Background
In the United States, up to 10 million foodborne-related 
cases were estimated to be responsible for approximately 
1300 deaths annually [1]. The presence of distinct bacte-
rial species in livestock farming is associated with food-
borne human infections resulting in gastrointestinal and 
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post-infectious extra-intestinal morbidities with rising 
prevalence rates worldwide [2, 3]. Particularly Campylo-
bacter infections are of substantial and increasing impor-
tance for food-borne diseases, whereas farm animals, 
especially poultry, are the main origin of human infection 
[4–6]. Following ingestion of raw or undercooked con-
taminated meat or surface water, symptoms of campylo-
bacteriosis may vary considerably [7, 8]. Whereas some 
patients are even asymptomatic or present with rather 
mild symptoms, others suffer from abdominal cramps, 
fever, watery of even bloody and inflammatory diarrhea 
that usually resolve within 1 week. In rare cases, however, 
post-infectious sequelae such as Gullain-Barré syndrome, 
Miller Fisher syndrome, or reactive arthritis may mani-
fest [9–11]. The pathogenesis of acute human campy-
lobacteriosis is strongly triggered by the activation of 
innate immune responses via Toll-like Receptor-4 (TLR-
4) mediated sensing of the bacterial lipooligosaccharide 
(LOS) that is expressed on the surface of C. jejuni [12, 
13]. Thus, innate immune responses upon C. jejuni infec-
tion are very similar to those observed following peracute 
infections with other LOS expressing pathogens such as 
Neisseria meningitidis and N. gonorrhoeae [14, 15].
Terpenoids are antimicrobial compounds that are effec-
tive against a broad range of microorganisms [16]. Car-
vacrol (4-isopropyl-2-methylphenol) is a monoterpenoid 
which constitutes a major compound in essential oils of 
thyme and oregano and other medicinal plants with many 
proven health beneficial effects [17, 18]. Carvacrol modu-
lates a multitude of different enzymatic functions which 
are causative for its anxiolytic, spasmolytic, cell regenera-
tive and anticancer activities and is further in the focus 
of infection research due to its natural antimicrobial 
effects against several food-borne pathogens including 
Campylobacter. In  vitro studies revealed that in bacte-
riostatic concentrations, carvacrol is capable of inducing 
changes in the fatty acid composition of the bacterial cell 
walls [19, 20]. In bactericidal concentrations, however, 
carvacrol even permeabilizes the outer membrane of 
Gram-negative bacteria [21]. In addition, carvacrol pos-
sesses ATPase-inhibiting activity [22, 23] and is proposed 
to act as a proton exchanger that reduces the pH gradi-
ent across the cytoplasmic membrane causing changes 
in proton motive force and in the ATP pool, which leads 
to cell death [23, 24]. Both, in  vitro and in  vivo stud-
ies revealed that carvacrol application could effectively 
reduce C. jejuni loads in intestinal samples derived from 
chicken [25–28]. Furthermore, carvacrol could effec-
tively reduce virulence gene expression and invasion of 
C. jejuni into chicken cells [26, 29]. Most importantly, 
the finding that carvacrol application resulted in inhi-
bition of motility and invasive properties of C. jejuni in 
vitro points towards carvacrol as a promising candidate 
molecule for the combat of human campylobacteri-
osis [30]. Recently, our group has established a clinical 
murine C. jejuni infection model allowing for pre-clinical 
studies of potential compounds against campylobacte-
riosis at the pharmaceutical level. After peroral C. jejuni 
infection, secondary abiotic IL-10−/− mice in which the 
intestinal microbiota had been depleted by antibiotic 
treatment could be stably colonized with C. jejuni at high 
pathogenic loads [12]. Given the lack of LOS resistance 
due to the absence of IL-10, these mice display C. jejuni 
induced acute enterocolitis within 1 week post-infection 
(p.i.) thereby mimicking clinical key features of severe 
campylobacteriosis [12, 31, 32]. In the present study, we 
applied this clinical murine model for human campylo-
bacteriosis in order to investigate the therapeutic and/or 
even preventive efficacies of carvacrol treatment against 
C. jejuni colonization and immunopathological sequelae 
in vivo.
Results
Antimicrobial properties of carvacrol against C. jejuni 
isolates
We first addressed potential directed antimicrobial 
effects of carvacrol against C. jejuni. In vitro studies with 
20 C. jejuni isolates including the reference strain 81–176 
revealed carvacrol  MIC90 values of 150 mg/l (pH 7.3).
Gastrointestinal pathogen loads following carvacrol 
treatment of C. jejuni infected mice
We next assessed potential health-beneficial proper-
ties (i.e., anti-C. jejuni and anti-inflammatory effects) 
of synthetic carvacrol (500 mg/l via the drinking water, 
ad  libitum) in the here applied clinical murine infec-
tion model for the study of severe human campylo-
bacteriosis. To accomplish this, secondary abiotic 
IL-10−/− mice were treated with carvacrol via the 
drinking water starting 4 days prior peroral C. jejuni 
infection with  109 bacterial cells by gavage on days 0 
and 1. At day 6 p.i., placebo (PLC) treated control mice 
harbored median pathogen loads of  109 and  108 CFU/g 
in their colon and ileum, respectively, that were 
approximately 0.5 and 2.0 log orders of magnitude 
lower in mice from the carvacrol cohort, respectively 
(p < 0.01 and p < 0.001, respectively; Fig. 1). Hence, car-
vacrol treatment lowers intestinal C. jejuni burdens up 
to 2 orders of magnitude.
Clinical effects upon carvacrol treatment of C. jejuni 
infected mice
We further performed a daily survey of C. jejuni induced 
symptoms in infected mice applying a standardized 
clinical scoring system assessing gross appearance of 
mice, stool consistency and abundance of blood in fecal 
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samples. As early as 48  h after the latest of two peroral 
pathogenic challenges (i.e., on day 3 p.i.), mice from the 
carvacrol group displayed less severe C. jejuni induced 
disease as indicated by lower clinical scores as com-
pared to PLC controls (p < 0.001; Additional file  1: Fig. 
S1), which also held true for days 5 and 6 p.i. (p < 0.001; 
Additional file 1: Fig. S1). At necropsy, PLC treated con-
trol mice suffered from acute enterocolitis characterized 
by wasting and bloody diarrhea (Fig. 2), whereas carvac-
rol treated mice, however, were clinically less compro-
mised as indicated by significantly reduced scores for 
gross appearance, abundance of fecal blood and diarrhea 
(p < 0.001 vs. PLC; Fig. 2). Notably, all control mice, but 
only 10.5% of carvacrol treated animals presented with 
diarrhea at day 6 p.i. (p < 0.001; Fig.  2c). Hence, carvac-
rol treatment alleviates C. jejuni induced symptoms of 
campylobacteriosis in the here applied clinical murine 
infection model.
Apoptotic and regenerative responses in colonic epithelial 
cells upon carvacrol treatment of C. jejuni infected mice
We next assessed whether the beneficial effects of carvac-
rol treatment on the macroscopic outcome of C. jejuni 
infected mice could also be observed on microscopic 
level. To address this, we stained colonic paraffin sec-
tions with defined antibodies against distinct cell inflam-
matory and proliferative/regenerative markers as well as 
against distinct immune cell populations applying in situ 
immunohistochemistry. At day 6 p.i., mice of either 
cohort exhibited increased numbers of caspase3 posi-
tive apoptotic cells in their colonic epithelia (p < 0.001 vs. 
Fig. 1 Gastrointestinal pathogen loads following carvacrol treatment 
of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni 
infection on days 0 and 1, secondary abiotic IL‑10−/− mice were 
treated with synthetic carvacrol (CARVA; white boxes) or placebo 
(PLC; grey boxes) via the drinking water. At day 6 post‑infection, C. 
jejuni were cultured from distinct luminal parts of the gastrointestinal 
tract and pathogen loads expressed as colony forming units per gram 
(CFU/g). Box plots represent the 75th and 25th percentiles of medians 
(black bar inside the boxes). The total range, significance levels 
(p‑values) determined by the Mann–Whitney U test and numbers of 
analyzed animals (in parentheses) are indicated. Data were pooled 
from four independent experiments
Fig. 2 Clinical outcome following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni infection on days 0 and 1, 
secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo (PLC; grey boxes) via the drinking water. 
Applying a standardized clinical scoring system (see “Methods”), a clinical outcome, b abundance of fecal blood and c stool consistency were 
quantitated at day 6 post‑infection. Box plots represent the 75th and 25th percentiles of medians (black bar inside the boxes). The total range, 
significance levels (p‑values) determined by the Mann–Whitney U test and numbers of analyzed animals (in parentheses) are indicated. Data were 
pooled from four independent experiments
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naive; Fig. 3a). However, numbers of apoptotic cells were 
five times lower in colonic epithelia of carvacrol as com-
pared to PLC treated mice at day 6 p.i. (p < 0.001; Fig. 3a; 
Additional file 2: Fig. S2A). We next stained large intes-
tinal paraffin sections with antibodies against Ki67 and 
quantified the respective cell proliferation and regenera-
tion counteracting C. jejuni induced cell damage micro-
scopically. In fact, C. jejuni infection was accompanied by 
a marked increase in Ki67 positive colonic epithelial cells 
(p < 0.001 vs. naive; Fig.  3b; Additional file  2: Fig. S2B). 
Importantly, numbers of proliferative/ regenerative cells 
were significantly elevated in carvacrol as compared to 
PLC mice at day 6 p.i. (p < 0.001; Fig. 3b; Additional file 2: 
Fig. S2B). Hence, carvacrol treatment ameliorates murine 
campylobacteriosis by inhibiting apoptosis and stimulat-
ing regenerative processes in the colonic epithelia.
Colonic immune responses upon carvacrol treatment of C. 
jejuni infected mice
We next quantitatively assessed large intestinal immune 
responses upon carvacrol treatment of C. jejuni infected 
mice. Within 6 days following C. jejuni infection, distinct 
immune cell populations such as CD3+ T lymphocytes 
cells and B220+  B lymphocytes had multifold increased 
in the colonic mucosa and lamina propria of mice from 
either cohort (p < 0.001; Fig. 3c, d; Additional file 2: Fig. 
S2C, D). Notably, colonic T lymphocytes, however, were 
lower following carvacrol as compared to PLC treatment 
at day 6 p.i. (p < 0.005, Fig. 3c; Additional file 2: Fig. S2C). 
The increased large intestinal abundances of immune 
cells upon C. jejuni infection were accompanied by 
enhanced secretion of pro-inflammatory mediators such 
as nitric oxide (NO), tumor necrosis factor (TNF) and 
interleukin (IL)-6 in colonic ex vivo biopsies obtained at 
day 6 p.i. (p < 0.05–0.001; Fig.  4a, c, d). Carvacrol treat-
ment of C. jejuni infected mice, however, resulted in 
lower colonic NO, interferon (IFN)-γ and TNF concen-
trations as compared to PLC application (p < 0.05–0.001; 
Fig.  4a–c). Of note, IFN-γ levels measured in the large 
intestines of carvacrol treated mice at day 6 p.i. did not 
differ from those of naive control mice (n.s.; Fig.  4b). 
Hence, carvacrol dampened C. jejuni induced colonic 
inflammation.
Ileal inflammatory immune responses upon carvacrol 
treatment of C. jejuni infected mice
In humans and murine infection models, C. jejuni 
induced intestinal inflammation is considered to pri-
marily affect the large intestinal tract resulting in acute 
enterocolitis [9]. Nevertheless, we expanded our intesti-
nal inflammatory survey of campylobacteriosis induced 
in secondary abiotic IL-10−/− mice to the small intes-
tines. At day 6 p.i., PLC, but not carvacrol treated mice 
displayed almost three time higher numbers of apop-
totic ileal epithelial cells (p < 0.001 vs. naive; Additional 
file  3: Fig. S3A and Additional file  4: Fig. S4A), which 
was accompanied by increased B cell counts in the 
mucosa and lamina propria of C. jejuni infected mice 
from the PLC, but not carvacrol cohort (p < 0.001; Addi-
tional file 3: Fig. S3D and Additional file 4: Fig. S4D). In 
addition, irrespective of the treatment regimen, mice 
displayed increased numbers of proliferating ileal epi-
thelial cells (p < 0.05–0.001; Additional file  3: Fig. S3B 
and Additional file 4: Fig. S4B) as well as of T lympho-
cytes (p < 0.001; Additional file  3: Fig. S3C and Addi-
tional file  4: Fig. S4C) in the small intestinal mucosa 
and lamina propria. The inflammation-ameliorating 
effects of carvacrol treatment also in the small intestinal 
tract of C. jejuni infected mice was further supported 
by increased secretion of pro-inflammatory cytokines 
such as TNF and IFN-γ in ileal ex  vivo biopsies taken 
from PLC (p < 0.05–0.005 vs. naive), but not carvacrol 
treated mice at day 6 p.i. (p < 0.05 vs. PLC; Additional 
file  5: Fig. S5). Hence, the campylobacteriosis amelio-
rating properties of carvacrol were not restricted to the 
large intestinal tract, but also effective in the distal small 
intestines.
Inflammatory immune responses in MLN upon carvacrol 
treatment of C. jejuni infected mice
We next surveyed disease ameliorating effects of carvac-
rol treatment in the MLN of C. jejuni infected mice. In 
support of our results obtained from the colon and ileum, 
less distinct secretion of pro-inflammatory mediators 
such as NO, IFN-γ, TNF and IL-6 could be assessed in 
MLN of carvacrol as compared to PLC treated mice at 
day 6 p.i. (p < 0.01–0.001; Fig. 5). Of note, the concentra-
tions of the three latter cytokines measured in carvacrol 
treated C. jejuni infected mice did not differ from those 
obtained from naive control animals (n.s.; Fig.  5b–d). 
Hence, the anti-inflammatory properties of carvacrol in 
C. jejuni infected mice were also effective in MLN drain-
ing the intestinal tract.
Extra‑intestinal including systemic inflammatory immune 
responses upon carvacrol treatment of C. jejuni infected 
mice
We further assessed disease-alleviating properties 
of carvacrol treatment in extra-intestinal includ-
ing systemic compartments of C. jejuni infected mice. 
Increased numbers of caspase3 positive apoptotic 
cells could be observed in paraffin sections taken from 
liver, kidneys and lungs at day 6 p.i. (p < 0.005–0.001), 
whereas apoptotic cell counts in either organs were 
lower in carvacrol as compared to PLC treated mice 
(p < 0.05–0.001; Fig.  6; Additional file  6: Fig. S6). Of 
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Fig. 3 Large intestinal apoptotic, proliferative/regenerative and immune cell responses upon carvacrol treatment of C. jejuni infected mice. Starting 
4 days prior peroral C. jejuni infection on days 0 and 1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) 
or placebo (PLC; grey boxes) via the drinking water. The average numbers of colonic epithelial a apoptotic cells (positive for caspase‑3, Casp3) and 
b proliferating/regenerating cells (positive for Ki67) as well as of c T lymphocytes (positive for CD3) and d B lymphocytes (positive for B220) in the 
mucosa of lamina propria from six high power fields (HPF, 400x magnification) per mouse were assessed microscopically in immunohistochemically 
stained large intestinal paraffin sections at day 6 post‑infection. Naive mice served as uninfected controls. The total range, significance levels 
(p‑values) determined by the Mann–Whitney U test and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four 
independent experiments
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note, in lungs numbers of apoptotic cells did not differ 
in carvacrol treated C. jejuni infected and naive mice 
(n.s.; Fig. 6c, Additional file 6: Fig. S6C).
We next measured pro-inflammatory cytokine secre-
tion in respective ex  vivo biopsies. At day 6 p.i., lower 
IFN-γ as well as TNF concentrations could be assessed 
Fig. 4 Colonic pro‑inflammatory mediator secretion following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni 
infection on days 0 and 1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo (PLC; grey boxes) 
via the drinking water. a Nitric oxide, b IFN‑γ, c TNF, and d IL‑6 concentrations were measured in supernatants of colonic ex vivo biopsies derived at 
day 6 post‑infection. Naive mice served as uninfected controls. The total range, significance levels (p‑values) determined by the Mann–Whitney U 
test and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four independent experiments
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in the liver of carvacrol as compared to PLC treated mice 
(p < 0.05 and p < 0.001, respectively; Fig. 7a, b), which also 
held true for renal IFN-γ protein levels (p < 0.05; Fig. 7c), 
but not TNF concentration (n.s.; Fig.  7d). Moreover, 
IFN-γ concentrations increased upon C. jejuni infec-
tion in the lungs of PLC (p < 0.05; Fig.  7e), but not car-
vacrol treated mice (n.s.; Fig.  7e), whereas elevated 
pulmonary  TNF levels could be obtained at day 6 p.i., 
Fig. 5 Pro‑inflammatory mediator secretion in mesenteric lymph nodes following carvacrol treatment of C. jejuni infected mice. Starting 4 days 
prior peroral C. jejuni infection on days 0 and 1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or 
placebo (PLC; grey boxes) via the drinking water. a Nitric oxide, b IFN‑γ, c TNF, and d IL‑6 concentrations were measured in supernatants of ex vivo 
biopsies derived from mesenteric lymph nodes (MLN) at day 6 post‑infection. Naive mice served as uninfected controls. The total range, significance 
levels (p‑values) determined by the Mann–Whitney U test and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from 
four independent experiments
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irrespective of the treatment regimen (p < 0.05; Fig.  7f ). 
Remarkably, the inflammation-dampening effects of car-
vacrol in C. jejuni infected mice could also be observed 
systemically as indicated by lower increases in pro-
inflammatory mediators such as IFN-γ, TNF, monocyte 
chemoattractant protein-1 (MCP-1) and IL-6 measured 
in serum samples taken from carvacrol as compared to 
PLC treated mice at day 6 p.i. (p < 0.05–0.005; Fig.  8). 
Hence, carvacrol treatment dampens C. jejuni induced 
pro-inflammatory responses also in extra-intestinal and 
even systemic compartments. 
Bacterial translocation into extra‑intestinal 
including systemic compartments of carvacrol treated 
mice following C. jejuni infection
We finally addressed whether carvacrol treatment had 
an impact on the translocation of viable pathogens origi-
nating from the gastrointestinal tract to extra-intestinal 
including systemic tissue sites. Whereas C. jejuni could 
be cultured from MLN of PLC and carvacrol treated 
mice in 45.8 and 42.1% of cases at day 6 p.i., respectively 
(Fig.  9a), pathogenic translocation rates were lower in 
spleens (15.8% vs. 20.8%), livers (5.3% vs. 8.3%), kidneys 
(0% vs. 8.3%) and lungs (0% vs 12.5%) taken from mice 
of the carvacrol versus PLC cohorts (Fig.  9b–e). Of 
note, all blood cultures were C. jejuni negative (Fig. 9f ). 
Hence, carvacrol treatment of C. jejuni infected mice is 
accompanied with less frequent translocation of viable 
pathogens from the intestinal tract to extra-intestinal 
compartments.
Discussion
In the European Union the annual financial burden to 
the public health systems and to loss of individual health 
and productivity due to foodborne C. jejuni infections 
are estimated to account for 2.4 billion Euro [33]. Given 
the progressive emergence of human campylobacteriosis, 
identification of non-synthetic  antibiotic molecules that 
Fig. 6 Extra‑intestinal apoptosis following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni infection on days 0 
and 1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo (PLC; grey boxes) via the drinking 
water. The average numbers of apoptotic cells (positive for caspase‑3, Casp3) from six high power fields (HPF, ×400 magnification) per mouse were 
assessed microscopically in immunohistochemically stained paraffin sections derived from a liver, b kidneys and c lungs at day 6 post‑infection. 
Naive mice served as uninfected controls. The total range, significance levels (p‑values) determined by the Mann–Whitney U test and numbers of 
analyzed animals (in parentheses) are indicated. Data were pooled from four independent experiments
(See figure on next page.)
Fig. 7 Extra‑intestinal pro‑inflammatory mediator secretion following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral 
C. jejuni infection on days 0 and 1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo 
(PLC; grey boxes) via the drinking water. a, c, e IFN‑γ and b, d, f TNF concentrations were measured in supernatants of ex vivo biopsies derived 
from a, b liver, c, d kidneys and e, f lungs at day 6 post‑infection. Naive mice served as uninfected controls. The total range, significance levels 
(p‑values) determined by the Mann–Whitney U test and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four 
independent experiments
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exert both, potent anti-Campylobacter and anti-inflam-
matory effects in infected individuals is highly appreci-
able in order to combat pathogen-induced morbidities. 
The phenolic compound carvacrol has been shown to 
exert antimicrobial activities by increasing the mem-
brane permeability of Gram-negative bacteria including 
Fig. 8 Systemic pro‑inflammatory mediator secretion following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni 
infection on days 0 and 1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo (PLC; grey boxes) 
via the drinking water. a IFN‑γ, b TNF, c MCP‑1 and d IL‑6 concentrations were measured serum samples taken at day 6 post‑infection. Naive mice 
served as uninfected controls. The total range, significance levels (p‑values) determined by the Mann–Whitney U test and numbers of analyzed 
animals (in parentheses) are indicated. Data were pooled from four independent experiments
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C. jejuni [34] and  thus, represents a promising option 
to replace conventionally used synthetic antibiotics for 
lowering the C. jejuni burden in livestock animals and 
avoiding the development of antibiotic resistant C. jejuni 
strains. In fact, the European Union has approved car-
vacrol as animal food supplement on the basis of results 
derived from carvacrol treatment studies in chicken 
farms in order to reduce the abundance of Campylobac-
ter in poultry farming and meat production [35]. Notably, 
carvacrol constitutes a major component of oregano and 
thyme oils representing a “generally as safe recognized” 
phytoherbal compound [36–40] that has been pharma-
ceutically approved for the treatment of gastrointestinal 
morbidities in humans [41, 42]. However, scientifically 
validated data regarding carvacrol application against C. 
jejuni induced enterocolitis in humans are scarce.
In the present pre-clinical intervention study we there-
fore applied a well-established clinical C. jejuni infection 
model of acute campylobacteriosis by using secondary 
abiotic IL-10−/− mice which display the clinical hallmarks 
of severe campylobacteriosis seen in human patients. In 
our study, we applied carvacrol via the drinking water 
in a concentration of 500 mg/l that was more than three 
times higher than the  MIC90 value of 150 mg/l that had 
been determined in 20 C. jejuni insolates before. Car-
vacrol treatment starting 4 days prior murine infection 
could sufficiently lower intestinal C. jejuni burdens up 
to 2 orders of magnitude until day 6 p.i. The antimicro-
bial properties of carvacrol directed against food-borne 
pathogens such as C. jejuni [26, 29, 30, 37] Salmonella 
spp. [37, 43–45], Escherichia coli O157:H7 [46] and Bacil-
lus cereus [47, 48] have been shown in  vitro recently. 
Synthetic carvacrol was, however, more effective against 
Gram-negative bacteria than against Gram-positive spe-
cies [49].
Fig. 9 Bacterial translocation following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni infection on days 0 and 
1, secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo (PLC; grey boxes) via the drinking water. 
At day 6 post‑infection, the abundance of C. jejuni was assessed in ex vivo biopsies derived from a MLN, b spleen, c liver, d kidneys, e lungs and f 
cardiac blood by culture. The cumulative relative translocation rate of viable pathogens into the respective compartment out of four independent 
experiments is indicated (in %)
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Remarkably, carvacrol treatment alleviated C. jejuni 
induced symptoms of campylobacteriosis including 
wasting and bloody diarrhea. Previous in  vitro studies 
revealed that carvacrol reduced C. jejuni virulence by 
inhibition of motility, cell attachment, tissue invasion 
and toxin production and disrupted bacterial ATP pro-
duction leading to bacterial cell death [22–27, 29, 30, 50]. 
In addition, carvacrol reduced Campylobacter coloniza-
tion in chicken in  vivo and inhibited biofilm formation 
[26]. Ameliorated murine campylobacteriosis was further 
characterized by less distinct C. jejuni induced apoptosis 
in both, colonic and ileal epithelia, whereas intestinal cell 
proliferative/regenerative properties counteracting path-
ogen-induced cell damage were enhanced upon carvacrol 
treatment. Furthermore, carvacrol application dampened 
intestinal pro-inflammatory immune responses upon C. 
jejuni infection as indicated by less abundance of T and 
B lymphocytes in the mucosa and lamina propria of both, 
the large and the small intestines and lower concentra-
tions of pro-inflammatory mediators including TNF and 
IL-6 in the intestinal tract and further, in the MLN drain-
ing the infected intestines. These results are supported 
by recent in  vitro studies showing that carvacrol treat-
ment of both, stimulated dendritic cells and macrophages 
resulted in less distinct TNF and IFN-γ secretion [51], 
whereas carvacrol could down-regulate lipopolysac-
charide (LPS) induced expression of pro-inflammatory 
cytokines such as TNF and IL-6 in broilers [52].
Notably, the inflammation-dampening properties of 
exogenous carvacrol was not restricted to the intestinal 
tract, but could also be observed in extra-intestinal organs 
such as liver, kidneys and lungs as indicated by less dis-
tinct apoptosis and secretion of the pro-inflammatory 
cytokines TNF and IFN-γ in respective organs. In sup-
port, carvacrol has been shown to improve survival during 
LPS-induced endotoxinemia and acute lung injury in mice 
and to result in less distinct secretion of pro-inflammatory 
cytokines including TNF and IL-6 [53].
Strikingly, the potent campylobacteriosis ameliorating 
effects upon carvacrol treatment could also be assessed 
systemically given that serum concentrations of TNF, IFN-
γ, MCP-1 and IL-6 were lower in carvacrol as compared 
to PLC treated C. jejuni infected mice. Of note, transloca-
tion of viable pathogens from the intestinal tract to extra-
intestinal organs occurred less frequently in the carvacrol 
versus PLC cohort. Even though all blood cultures were C. 
jejuni negative, one needs to take further into account that 
soluble bacterial molecules such as LOS and other cell wall 
constituents might have been transported via the circula-
tion and been responsible for the deleterious outcome of 
severe campylobacteriosis in PLC control mice.
Overall, it is tempting to speculate that the observed 
disease-ameliorating properties of carvacrol are due to 
an orchestrated sum effect of distinct anti-inflammatory 
features of the compound: (i) lower intestinal pathogen 
loads and hence, (ii) less LOS exposure less distinctly 
inducing pro-inflammatory mediator  secretion, (iii) 
hypothetical direct anti-LOS effect of carvacrol, (iv) 
interfering with distinct C. jejuni virulence factors by 
blocking motility, adhesion, invasion, LOS expression, 
leading to (v) less recruitment of immune cells resulting 
in (vi) less secretion of pro-inflammatory mediators, (vii) 
less cytotoxicity including apoptosis, (viii) more counter-
regulatory cell proliferation/regeneration, (ix) less patho-
genic translocation, and (x) less extra-intestinal including 
(xi) systemic immune responses.
Taken together these beneficial effects result in a sig-
nificant amelioration of disease and better overall clini-
cal outcome of mice in the clinical infection model for 
human campylobacteriosis.
Conclusion
The lowered C. jejuni loads and alleviated symptoms 
observed in the here applied clinical murine model for 
human campylobacteriosis highlight the application of 
carvacrol as a promising option not only for the treat-
ment of campylobacteriosis in humans and hence, for 
prevention of post-infectious sequelae, but also for the 
reduction of C. jejuni colonization in lifestock animals.
Methods
Determination of minimal inhibitory concentrations 
of carvacrol
For determination of minimal inhibitory concentration 
(MIC) values of carvacrol, 20 C. jejuni isolates including 
the reference strain 81–176 used for infection of mice 
(see below) were tested for their antimicrobial suscep-
tibility applying the broth microdilution method. Pro-
cedures regarding inoculum density, growth medium, 
incubation time and conditions were performed in 
accordance with the recommendations given in the Clini-
cal and Laboratory Standards Institute (CLSI) document 
VET01-Ed5. Twofold serial dilutions ranging from 0.008 
to 8.0 mmol/l (1–1202 µg/ml) for carvacrol were tested. 
Stock solutions were prepared in Mueller–Hinton broth 
and adjusted to pH 7.3. The  C. jejuni reference strain 
DSM 4688 was used for quality control purposes. The 
MIC value of the reference strain was tested in advance 
in three independent experiments using the broth micro-
dilution method and the broth macrodilution method.
Generation of secondary abiotic mice
IL-10−/− mice (female and male, all in C57BL/6j back-
ground) were reared under specific pathogen free 
(SPF) conditions in the same unit of the Forschun-
gseinrichtungen für Experimentelle Medizin (FEM, 
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Charité—University Medicine Berlin). In order to coun-
teract physiological colonization resistance and thus 
assure stable gastrointestinal C. jejuni colonization [13], 
secondary abiotic mice with a depleted gut microbiota 
were generated as described earlier [13, 54]. In brief, 
immediately post weaning 3-week-old mice were sub-
jected to a 10-week course of broad-spectrum antibiotic 
treatment by adding ampicillin plus sulbactam (1  g/l; 
Ratiopharm, Germany), vancomycin (500  mg/l; Cell 
Pharm, Germany), ciprofloxacin (200  mg/l; Bayer Vital, 
Germany), imipenem (250  mg/l; MSD, Germany) and 
metronidazole (1  g/l; Fresenius, Germany) to the auto-
claved drinking water (ad libitum). Two days before path-
ogenic challenge the antibiotic cocktail was replaced by 
autoclaved tap water to assure antibiotic washout.
Carvacrol treatment
Four days prior C. jejuni infection treatment with car-
vacrol (Sigma-Aldrich, Munich, Germany; daily dose of 
100  mg carvacrol per kg body weight) was initiated by 
dissolving the compound in Tween 80 (0.2% v/v) to a final 
concentration of 500 mg/l autoclaved tap water (ad libi-
tum). Placebo control mice received Tween 80 only.
Campylobacter jejuni infection
Twelve-week old mice were perorally challenged with 
 109 colony forming units (CFU) of the highly pathogenic 
C. jejuni reference strain 81–176 by gavage (in a total vol-
ume of 0.3 ml phosphate buffered saline (PBS), Gibco, Life 
Technologies, UK). Animals were continuously main-
tained in a sterile environment (autoclaved food and drink-
ing water or sterile antibiotic cocktail) and handled under 
strict aseptic conditions in order to avoid contaminations.
Clinical conditions
Before and after Campylobacter jejuni infection clinical 
conditions of mice were assessed on a daily basis apply-
ing a standardized cumulative clinical score (maximum 
12 points) addressing the abundance of blood in feces 
(0: no blood; 2: microscopic detection of blood by the 
Guajac method using Haemoccult, Beckman Coulter/
PCD, Germany; 4: macroscopic blood visible), diarrhea 
(0: formed feces; 2: pasty feces; 4: liquid feces), and the 
clinical aspect (0: normal; 2: ruffled fur, less locomotion; 
4: isolation, severely compromised locomotion, pre-final 
aspect) as described earlier [55].
Sampling procedures
At day 6 p.i., mice were sacrificed by isofluran inhala-
tion (Abbott, Germany). Luminal gastrointestinal sam-
ples (i.e., from stomach, duodenum, ileum and colon) 
and ex vivo biopsies were taken from colon, mesenteric 
lymph nodes (MLN), liver, kidneys, lungs, and spleen 
under sterile conditions. Intestinal samples were col-
lected from each mouse in parallel for microbiological, 
immunohistopathological and immunological analyses. 
The absolute colonic lengths were measured with a ruler 
(in cm).
Pathogenic colonization and translocation
Campylobacter jejuni loads were surveyed in fecal sam-
ples over time p.i., and upon necropsy in luminal samples 
taken from the stomach, duodenum, ileum and colon as 
well as in homogenates of ex vivo biopsies derived from 
MLN, spleen, liver, kidney  and lung as well as in car-
diac blood samples by culture as described previously 
[13, 56]. In brief, intraluminal gastrointestinal samples 
and respective ex  vivo biopsies were homogenized in 
sterile PBS with a pistil and serial dilutions plated onto 
karmali agar (Oxoid, Wesel, Germany) and incubated in 
a microaerophilic atmosphere for at least 48  h. Cardiac 
blood (0.2  ml) was immediately streaked onto karmali 
agar plates. The detection limit of viable pathogens was 
approximately 100 CFU/g.
Immunohistochemistry
In situ immunohistochemical analyses were performed 
in ex vivo biopsies derived from colon, ileum, liver, kid-
neys, and lungs that had been immediately fixed in 5% 
formalin and embedded in paraffin as stated elsewhere 
[32, 57–59]. In brief, in order to detect apoptotic epi-
thelial cells, proliferation epithelial cells, T lympho-
cytes, and B lymphocytes, paraffin sections  (5  μm) 
were stained with primary antibodies directed against 
cleaved caspase 3 (Asp175, Cell Signaling, Beverly, MA, 
USA, 1:200), Ki67 (TEC3, Dako, Denmark, 1:100), CD3 
(#N1580, Dako, 1:10), and B220 (No. 14–0452-81, eBio-
science; 1:200), respectively. After incubation with the 
primary antibody (30 min), sections were incubated for 
another 30 min with the respective secondary antibody 
(for anti-cleaved caspase 3 and anti-CD3 staining: bioti-
nylated donkey anti-rabbit antibody; for anti-Ki67 and 
anti-B220 staining: biotinylated rabbit anti-rat antibody; 
all purchased from Dianova, Hamburg, Germany). The 
Streptavidin–Alkaline Phosphatase Kit (Dako) using 
Fast Red as chromogen was applied as detection sys-
tem. Negative controls were generated in samples in 
which the respective primary antibody had been omit-
ted. Positively stained cells were then examined by light 
microscopy (magnification 100× and 400×), and for 
each mouse the average number of respective positively 
stained cells was determined within at least six high 
power fields (HPF, 0.287  mm2, 400× magnification) by a 
blinded independent investigator.
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Pro‑inflammatory mediators
Colonic and ileal ex vivo biopsies were cut longitudinally 
and washed in PBS. Ex  vivo biopsies derived from liver 
(approximately 1  cm3), kidney (one half after longitudinal 
cut), lung, MLN (3–4 lymph nodes) or strips of approxi-
mately 1  cm2 colonic or ileal tissues were placed in 
24-flat-bottom well culture plates (Nunc, Germany) con-
taining 500 μl serum-free RPMI 1640 medium (Gibco, 
life technologies, UK) supplemented with penicillin (100 
U/ml) and streptomycin (100  µg/ml; PAA Laboratories, 
Germany). After 18 h at 37 °C, culture supernatants and 
serum samples were tested for IFN-γ, TNF, IL-6, and 
MCP-1 by the Mouse Inflammation Cytometric Bead 
Assay (CBA; BD Biosciences, Germany) on a BD FACS-
Canto II flow cytometer (BD Biosciences). Systemic pro-
inflammatory cytokine concentrations were measured in 
serum samples. NO concentrations were assessed by the 
Griess reaction [54, 60].
Statistical analysis
Medians and levels of significance were determined 
using Mann–Whitney test (GraphPad Prism v7, USA) 
as indicated. Two-sided probability (p) values ≤ 0.05 
were considered significant. Experiments were repro-
duced three times.
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Additional files
Additional file 1: Figure S1. Kinetic survey of clinical conditions fol‑
lowing carvacrol treatment of C. jejuni infected mice. Starting 4 days 
prior peroral C. jejuni infection on day (d) 0 and d1, secondary abiotic 
IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) 
or placebo (PLC; grey boxes) via the drinking water. Severities of clinical 
symptoms were surveyed daily from d0 until d6 applying a standardized 
clinical scoring system postinfection (see “Methods”). Box plots represent 
the 75th and 25th percentiles of medians (black bar inside the boxes). 
Total range, significance levels (p‑values; determined between groups at 
respective time points; ***p < 0.001) by the Mann–Whitney U test and 
numbers of analyzed animals (in parentheses) are indicated. Data were 
pooled from four independent experiments. 
Additional file 2: Figure S2. Representative photomicrographs illus‑
trating apoptotic and proliferating epithelial as well as immune cells 
responses in large intestines upon carvacrol treatment of C. jejuni infected 
mice. Starting 4 days prior peroral C. jejuni infection on days 0 and 1, 
secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol 
(CARVA) or placebo (PLC) via the drinking water. Naive mice served as 
uninfected controls. Photomicrographs reepresentative for four independ‑
ent experiments illustrate the average numbers of (A) apoptotic epithelial 
cells (Casp3+), (B) proliferating epithelial cells (Ki67+), (C) T lymphocytes 
(CD3+), and (D) B lymphocytes (B220+) in at least six high power fields 
(HPF) as quantitatively assessed in colonic paraffin sections applying 
in situ immunohistochemistry at day 6 post‑infection (A: 400× magnifica‑
tion, scale bar 20 μm; B–D: 100× magnification, scale bar 100 μm). 
Additional file 3: Figure S3. Ileal apoptotic, proliferative and immune 
cell responses upon carvacrol treatment of C. jejuni infected mice. Starting 
4 days prior peroral C. jejuni infection on days 0 and 1, secondary abiotic 
IL‑10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) 
or placebo (PLC; grey boxes) via the drinking water. The average numbers 
of (A) apoptotic (positive for caspase3, Casp3) and (B) proliferative/regen‑
erative (positive for Ki67) ileal epithelial cells as well as of (C) T lympho‑
cytes (positive for CD3) and (D) B lymphocytes (positive for B220) in the 
ileal mucosa and lamina propria from six high power fields (HPF, 400× 
magnification) per mouse were assessed microscopically in immunohisto‑
chemically stained small intestinal paraffin sections at day 6 post‑infection. 
Naive mice served as uninfected controls. The total range, significance 
levels (p‑values) determined by the Mann–Whitney U test and numbers 
of analyzed animals (in parentheses) are indicated. Data were pooled from 
four independent experiments. 
Additional file 4: Figure S4. Representative photomicrographs illus‑
trating apoptotic and proliferating epithelial as well as immune cells 
responses in large intestines upon carvacrol treatment of C. jejuni infected 
mice. Starting 4 days prior peroral C. jejuni infection on days 0 and 1, 
secondary abiotic IL‑10−/− mice were treated with synthetic carvacrol 
(CARVA) or placebo (PLC) via the drinking water. Naive mice served as 
uninfected controls. Photomicrographs reepresentative for four independ‑
ent experiments illustrate the average numbers of (A) apoptotic epithelial 
cells (Casp3+), (B) proliferating epithelial cells (Ki67+), (C) T lymphocytes 
(CD3+), and (D) B lymphocytes (B220+) in at least six high power fields 
(HPF) as quantitatively assessed in ileal paraffin sections applying in situ 
immunohistochemistry at day 6 post‑infection (A: 400× magnification, 
scale bar 20 μm; B–D: 100× magnification, scale bar 100 μm). 
Additional file 5: Figure S5. Ileal pro‑inflammatory mediator secretion 
in carvacrol treated mice following C. jejuni infection. Starting 4 days prior 
peroral C. jejuni infection on days 0 and 1, secondary abiotic IL‑10−/− mice 
were treated with synthetic carvacrol (CARVA; white boxes) or placebo 
(PLC; grey boxes) via the drinking water. (A) IFN‑γ and (B) TNF concentra‑
tions were measured in supernatants of ileal ex vivo biopsies derived at 
day 6 post‑infection. Naive mice served as uninfected controls. The total 
range, significance levels (p‑values) determined by the Mann–Whitney U 
test and numbers of analyzed animals (in parentheses) are indicated. Data 
were pooled from four independent experiments. 
Additional file 6: Figure S6. Representative photomicrographs illustrat‑
ing apoptotic cells responses in extra‑intestinal compartments upon 
carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral 
C. jejuni infection on days 0 and 1, secondary abiotic IL‑10−/− mice were 
treated with synthetic carvacrol (CARVA) or placebo (PLC) via the drink‑
ing water. Naive mice served as uninfected controls. Photomicrographs 
reepresentative for four independent experiments illustrate the average 
numbers of apoptotic cells (Casp3+) in (A) liver, (B) kidney and (C) lung 
in at least six high power fields (HPF) as quantitatively assessed in paraffin 
sections of respective ex vivo biopsies applying in situ immunohistochem‑
istry at day 6 post‑infection (100× magnification, scale bar 100 μm).
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